A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors
详细信息 查看全文
- 作者：Amir Mortazavi (1)
Yonghua Ling (2)
Ludmila Katherine Martin (1)
Lai Wei (3)
Mitch A. Phelps (2) (4)
Zhongfa Liu (2) (4)
Erica J. Harper (1)
S. Percy Ivy (5)
Xin Wu (1)
Bing-Sen Zhou (6)
Xiyong Liu (6)
Deidre Deam (1)
J. Paul Monk (1)
William J. Hicks (1)
Yun Yen (6)
Gregory A. Otterson (1)
Michael R. Grever (7)
Tanios Bekaii-Saab (1) - 关键词：Triapine ; Gemcitabine ; Phase I ; Clinical Trial
- 刊名：Investigational New Drugs
- 出版年：2013
- 出版时间：June 2013
- 年：2013
- 卷：31
- 期：3
- 页码：685-695
- 全文大小：240KB
- 参考文献：1. Bokemeyer C et al (1999) Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 17(2):512鈥?16
2. Burris HA 3rd et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403鈥?413
3. Cardenal F et al (1999) Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 17(1):12鈥?8
4. Heinemann V (2003) Role of gemcitabine in the treatment of advanced and metastatic breast cancer. Oncology 64(3):191鈥?06 CrossRef
5. Markman M (2002) Second-line treatment of ovarian cancer with single-agent gemcitabine. Semin Oncol 29(1 Suppl 1):9鈥?0 CrossRef
6. Scheithauer W (2002) Review of gemcitabine in biliary tract carcinoma. Semin Oncol 29(6 Suppl 20):40鈥?5
7. von der Maase H (2003) Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev Anticancer Ther 3(1):11鈥?9 CrossRef
8. Bjorklund S et al (1990) S-phase-specific expression of mammalian ribonucleotide reductase R1 and R2 subunit mRNAs. Biochemistry 29(23):5452鈥?458 CrossRef
9. Cory JG et al (1994) Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones. Biochem Pharmacol 48(2):335鈥?44 CrossRef
10. Duxbury MS et al (2004) RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 23(8):1539鈥?548 CrossRef
11. Jung CP, Motwani MV, Schwartz GK (2001) Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 7(8):2527鈥?536
12. Heinemann V et al (1990) Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2鈥?2鈥?difluorodeoxycytidine. Mol Pharmacol 38(4):567鈥?72
13. Gandhi V et al (2002) Prolonged infusion of gemcitabine: Clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol 20(3):665鈥?73 CrossRef
14. Grunewald R et al (1992) Gemcitabine in leukemia: A phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10(3):406鈥?13
15. Tempero M et al (2003) Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21(18):3402鈥?408 CrossRef
16. Poplin E et al (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: A trial of the eastern cooperative oncology group. J Clin Oncol 27(23):3778鈥?785 CrossRef
17. Elford HL et al (1970) Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas. J Biol Chem 245(20):5228鈥?233
18. Bergman AM, Pinedo HM, Peters GJ (2002) Determinants of resistance to 2鈥?2鈥?difluorodeoxycytidine (gemcitabine). Drug Resist Updat 5(1):19鈥?3 CrossRef
19. Goan YG et al (1999) Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 59(17):4204鈥?207
20. Gandhi V et al (1992) Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res 52(4):897鈥?03
21. Iwasaki H et al (1997) Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 90(1):270鈥?78
22. Kubota M et al (1988) Differential modulation of 1-beta-D-arabinofuranosylcytosine metabolism by hydroxyurea in human leukemic cell lines. Biochem Pharmacol 37(9):1745鈥?749 CrossRef
23. Walsh CT, Craig RW, Agarwal RP (1980) Increased activation of 1-beta-D-arabinofuranosylcytosine by hydroxyurea in L1210 cells. Cancer Res 40(9):3286鈥?292
24. Zhou B et al (2002) Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells. Anticancer Res 22(3):1369鈥?377
25. Moore EC, Booth BA, Sartorelli AC (1971) Inhibition of deoxyribonucleotide synthesis by pyridine carboxaldehyde thiosemicarbazones. Cancer Res 31(3):235鈥?38
26. Finch RA et al (2000) Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol 59(8):983鈥?91 CrossRef
27. Zhu L et al (2009) Inhibitory mechanisms of heterocyclic carboxaldehyde thiosemicabazones for two forms of human ribonucleotide reductase. Biochem Pharmacol 78(9):1178鈥?185 CrossRef
28. Chen C.-H, King I, and Belcourt M (2002) Triapine, a ribonucleotide reductase inhibitor, enhances incorporation of gemcitabine into DNA and cytotoxicity to KB cells. European journal of cancer (Oxford, England : 1990), 38: S26.
29. Feun L et al (2002) Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Cancer Chemother Pharmacol 50(3):223鈥?29 CrossRef
30. Murren J et al (2003) Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for 5聽days in patients with advanced solid tumors. Clin Cancer Res 9(11):4092鈥?100
31. Wadler S et al (2004) Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J Clin Oncol 22(9):1553鈥?563 CrossRef
32. Yen Y et al (2004) A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother Pharmacol 54(4):331鈥?42 CrossRef
33. Therasse P et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. J Natl Cancer Inst 92(3):205鈥?16 CrossRef
34. Birch N, Wang X, Chong H-S (2006) Iron chelators as therapeutic iron depletion agents. Expert Opinion on Therapeutic Patents 16(11):1533鈥?556 CrossRef
35. Shao J et al (2006) A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol Cancer Ther 5(3):586鈥?92 CrossRef
36. US Food and Drug Administration Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM), / Guidance for Industry on Bioanalytical Method Validation, 2001.
37. Zhou B et al (2006) Production of a monoclonal antibody against the hRRM2 subunit of ribonucleotide reductase and immunohistochemistry study of human cancer tissues. Hybridoma (Larchmt) 25(5):264鈥?70 CrossRef
38. Ko AH et al (2006) Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol 24(3):379鈥?85 CrossRef
39. Lopes G et al (2007) Oxaliplatin and fixed-rate infusional gemcitabine in the second-line treatment of patients with metastatic colon cancer: Final results of a phase II trial prematurely closed as a result of poor accrual. Clin Colorectal Cancer 6(9):641鈥?45 CrossRef
40. Louvet C et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23(15):3509鈥?516 CrossRef
41. Nutting CM et al (2009) Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma. Ann Oncol 20(7):1275鈥?279 CrossRef
42. Mackenzie MJ et al (2007) A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium. Invest New Drugs 25(6):553鈥?58 CrossRef
43. Traynor AM et al (2010) A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern cooperative oncology group study 1503. Invest New Drugs 28(1):91鈥?7 CrossRef
44. Ma B et al (2008) A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. Invest New Drugs 26(2):169鈥?73 CrossRef
45. Ocean AJ et al (2011) Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 68(2):379鈥?88 CrossRef
46. Giles FJ et al (2003) Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res 27(12):1077鈥?083 CrossRef
47. Kolesar J et al (2011) Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine(R)) in cancer patients. Cancer Chemother Pharmacol 67(2):393鈥?00 CrossRef - 作者单位：Amir Mortazavi (1)
Yonghua Ling (2)
Ludmila Katherine Martin (1)
Lai Wei (3)
Mitch A. Phelps (2) (4)
Zhongfa Liu (2) (4)
Erica J. Harper (1)
S. Percy Ivy (5)
Xin Wu (1)
Bing-Sen Zhou (6)
Xiyong Liu (6)
Deidre Deam (1)
J. Paul Monk (1)
William J. Hicks (1)
Yun Yen (6)
Gregory A. Otterson (1)
Michael R. Grever (7)
Tanios Bekaii-Saab (1)
1. Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University and The Comprehensive Cancer Center, A454 Starling-Loving Hall, 320 West 10th Ave, Columbus, OH, 43210, USA
2. Pharmacoanalytical Shared Resources, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, 43210, USA
3. Center for Biostatistics, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, 43210, USA
4. Division of Pharmaceutics, College of Pharmacy, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, 43210, USA
5. Cancer Therapeutics Evaluation Program, National Cancer Institute, Rockville, MD, 20852, USA
6. City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA
7. Division of Hematology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, 43210, USA - ISSN：1573-0646
文摘